MK-3475 + Lenvatinib + Carboplatin + Paclitaxel
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Untreated Advanced or Recurrent Thymic Carcinomas
Conditions
Untreated Advanced or Recurrent Thymic Carcinomas
Trial Timeline
Sep 4, 2023 → Jun 30, 2028
NCT ID
NCT05832827About MK-3475 + Lenvatinib + Carboplatin + Paclitaxel
MK-3475 + Lenvatinib + Carboplatin + Paclitaxel is a phase 2 stage product being developed by Merck for Untreated Advanced or Recurrent Thymic Carcinomas. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05832827. Target conditions include Untreated Advanced or Recurrent Thymic Carcinomas.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05832827 | Phase 2 | Recruiting |
Competing Products
15 competing products in Untreated Advanced or Recurrent Thymic Carcinomas